CZ20033256A3 - Process for preparing a thiazole ppar-ligand and polymorphs thereof - Google Patents

Process for preparing a thiazole ppar-ligand and polymorphs thereof Download PDF

Info

Publication number
CZ20033256A3
CZ20033256A3 CZ20033256A CZ20033256A CZ20033256A3 CZ 20033256 A3 CZ20033256 A3 CZ 20033256A3 CZ 20033256 A CZ20033256 A CZ 20033256A CZ 20033256 A CZ20033256 A CZ 20033256A CZ 20033256 A3 CZ20033256 A3 CZ 20033256A3
Authority
CZ
Czechia
Prior art keywords
compound
methyl
formula
compounds
pharmaceutically acceptable
Prior art date
Application number
CZ20033256A
Other languages
Czech (cs)
English (en)
Inventor
Thierry Boyer
Caroline Jane Day
Andrew Jonathan Whitehead
Richard Anthony Henson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of CZ20033256A3 publication Critical patent/CZ20033256A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
CZ20033256A 2001-05-31 2002-05-29 Process for preparing a thiazole ppar-ligand and polymorphs thereof CZ20033256A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0113232.3A GB0113232D0 (en) 2001-05-31 2001-05-31 Chemical process

Publications (1)

Publication Number Publication Date
CZ20033256A3 true CZ20033256A3 (en) 2004-04-14

Family

ID=9915637

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20033256A CZ20033256A3 (en) 2001-05-31 2002-05-29 Process for preparing a thiazole ppar-ligand and polymorphs thereof

Country Status (22)

Country Link
US (1) US7244849B2 (cg-RX-API-DMAC7.html)
EP (1) EP1395572B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004532265A (cg-RX-API-DMAC7.html)
KR (1) KR20040007631A (cg-RX-API-DMAC7.html)
CN (1) CN1551871A (cg-RX-API-DMAC7.html)
AT (1) ATE315556T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002317764B2 (cg-RX-API-DMAC7.html)
BR (1) BR0209892A (cg-RX-API-DMAC7.html)
CA (1) CA2448101A1 (cg-RX-API-DMAC7.html)
CO (1) CO5540298A2 (cg-RX-API-DMAC7.html)
CZ (1) CZ20033256A3 (cg-RX-API-DMAC7.html)
DE (1) DE60208682T2 (cg-RX-API-DMAC7.html)
ES (1) ES2256493T3 (cg-RX-API-DMAC7.html)
GB (1) GB0113232D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0400117A3 (cg-RX-API-DMAC7.html)
IL (1) IL158641A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03010943A (cg-RX-API-DMAC7.html)
NO (1) NO20035313L (cg-RX-API-DMAC7.html)
NZ (1) NZ529486A (cg-RX-API-DMAC7.html)
PL (1) PL367114A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002096893A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200308570B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
CN1662487A (zh) 2002-06-19 2005-08-31 伊莱利利公司 酰胺连接基过氧化物酶体增殖物激活受体调节剂
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
EP1734930A2 (en) * 2004-04-09 2006-12-27 Smithkline Beecham Corporation Low dose pharmaceutical products
US20090012133A1 (en) * 2006-01-10 2009-01-08 Smithkline Beecham Corporation Polymorphic Form of -Acetic Acid
WO2012168948A2 (en) * 2011-06-06 2012-12-13 Hetero Research Foundation Process for febuxostat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ グループ リミテッド hPPARアルファアゴニストとしての置換オキサゾールおよびチアゾール
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
GB0113233D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
WO2002096893A1 (en) 2002-12-05
ZA200308570B (en) 2005-02-03
DE60208682T2 (de) 2006-08-24
HUP0400117A3 (en) 2005-09-28
PL367114A1 (en) 2005-02-21
US7244849B2 (en) 2007-07-17
NO20035313L (no) 2003-12-09
IL158641A0 (en) 2004-05-12
US20040242657A1 (en) 2004-12-02
CO5540298A2 (es) 2005-07-29
NZ529486A (en) 2005-12-23
MXPA03010943A (es) 2004-02-27
JP2004532265A (ja) 2004-10-21
EP1395572B1 (en) 2006-01-11
CA2448101A1 (en) 2002-12-05
CN1551871A (zh) 2004-12-01
ES2256493T3 (es) 2006-07-16
DE60208682D1 (de) 2006-04-06
ATE315556T1 (de) 2006-02-15
KR20040007631A (ko) 2004-01-24
NO20035313D0 (no) 2003-11-28
GB0113232D0 (en) 2001-07-25
EP1395572A1 (en) 2004-03-10
BR0209892A (pt) 2004-06-08
HUP0400117A2 (hu) 2005-03-29
AU2002317764B2 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
EP1244642B1 (en) Substituted oxazoles and thiazoles derivatives as hppar alpha activators
JP3255930B2 (ja) PPAR―γに対するアゴニスト活性を有する置換4―ヒドロキシフェニルアルカン酸誘導体
CZ20033250A3 (en) Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
JPS6154792B2 (cg-RX-API-DMAC7.html)
JPWO2002046176A1 (ja) ペルオキシソーム増殖剤応答性受容体の活性化剤
JP2000515133A (ja) 血糖降下性および脂質低下性の化合物
JP2004517100A (ja) hPPARアルファアゴニストとしての置換オキサゾールおよびチアゾール
AU2002317764B2 (en) Process for preparing a thialzole PPAR-ligand and polymorphs thereof
KR100859591B1 (ko) Hppar-알파 수용체의 옥사졸/티아졸-유도체 활성제
AU2002317764A1 (en) Process for preparing a thialzole PPAR-ligand and polymorphs thereof
JP2026509366A (ja) Sstr4アゴニスト及びその塩の調製のための方法
US10689374B1 (en) Pyrimidine-thiazolidinone derivatives
JP2007508270A (ja) I.a.ジスリピデミアの治療におけるhppar作用物質として使用するためのチアゾール−2−カルボキシアミド誘導体
KR20080099871A (ko) 신규의 헤테로싸이클릭 싸이클로알킬 유도체, 이의 제조 방법 및 이를 포함하는 약제학적 조성물
JPWO2001007423A1 (ja) トロンボポエチン受容体アゴニスト作用を有する医薬組成物